From exosome characterization to monoclonal antibodies (mAb) production: looking for biotechnological strategies to bone disorders treatment

• Grant number: 22/14304-0
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
• Start date: April 01, 2023
• End date: March 31, 2027
• Field of knowledge: Biological Sciences - Biochemistry - Chemistry of Macromolecules
• Principal Investigator: Willian Fernando Zambuzzi
• Grantee: Matheus Luquirini Penteado dos Santos
• Host Institution: Instituto de Biociências (IBB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Associated scholarship(s): 25/06351-7 - Exploring the role of AoSMC-derived small extracellular vesicles in vascular-bone crosstalk under normal and pathological conditions, BE.EP.DD

Abstract

The skeletal system houses a set of cells that, in a hierarchical manner, support the formation and definition of life. In this context, we know that it is necessary for osteogenesis as well as fracture healing through regenerative mechanisms; it is known that these problems can increase with aging, as bone mass and fracture damage can increase. The large amount of public health has increased public health problem, when the attention of public health life has increased significantly. Ultimately, it is known that the event is being developed and developed by the mechanism of formation of cryptographic cells from bone to bone to osteogenesis. These studies show interest in investigating how osteogenic and endothelial lineages justify our interest in knowing the scenario of studies presented in this process. Data obtained by our team shows that vascular smooth muscle cells interfere with osteocytogenesis, through communication made by exosomes. As osteoclasts are multinucleated cells related to reabsorb a mineralized matrix, we hypothesized that exosomes released by smooth muscle cells may interfere with osteoblast biology through the set of exosome membrane proteins. In this sense, our objective is to analyze the repertoire of proteins inserted in the plasma membrane of osteoblasts and exosome. From these results, we hope to propose therapies related to bone disorders, such as nanodrugs, biomaterials and monoclonal's antibodies. (AU)